Heterocyclic compounds and uses thereof
New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
1. A compound of Formula I:
wherein:
X or Y, whichever is present, is selected from the group consisting of O and S;
R 1 is pyridine or pyrazine, and is substituted with one or more halo, amino, aminocarbonyl, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, D, —OH, —CN, MeNH—, Me 2 N—, acetyl, acetylamino, aminosulfonyloxy, C1-C4 alkoxycarbonyl, or carboxyl;
R 2 is optionally substituted heteroaryl; and
R 3 is unsubstituted phenyl or phenyl substituted with one, two or three substituents;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , which is a compound of Formula II:
wherein Z 1 is CR 8 or N; and
R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, deuterium, halo, cyano, hydroxy, C1-C4 alkyl, amino, and C1-C4 alkoxy;
R 2 , R 3 , X and Y are as defined for Formula (I);
or the pharmaceutically acceptable salts, and isomers, deuterated versions and tautomers thereof.
3. The compound of claim 1 , which is a compound of Formula III:
wherein Z 2 is CR 9 or N; and
R 9 , R 10 , R 11 , and R 12 are independently selected from the group consisting of hydrogen, halo, D, cyano, hydroxy, —NR″C(O)R′, optionally substituted alkyl, optionally substituted amino, optionally substituted heteroaryl, and optionally substituted alkoxy;
R′ is optionally substituted C1-C4 alkyl and R″ is hydrogen or optionally substituted C1-C4 alkyl;
R 1 , R 3 , X and Y are as defined for Formula (I);
and any two of R 9 , R 10 , R 11 , and R 12 that are attached to adjacent atoms of a ring in Formula III can be taken together to form an additional optionally substituted 5-6 membered ring.
4. The compound of claim 3 , wherein R 10 is —NHR 13 , wherein R 13 is selected from the group consisting of optionally substituted alkyl, optionally substituted heterocyclyl, —C(O)R′, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted aryl, and optionally substituted heteroaryl.
5. A compound of Formula IV:
wherein Z 1 and Z 2 are each independently N or CH;
where X or Y, whichever is present, is selected from the group consisting of O and S;
R 3 is optionally substituted phenyl, or a C1-C6 hydrocarbyl group;
R 6 is amino;
R 7 is H, D, halo, amino or C1-C4 alkoxy; and
R 10 is NHR 15 , wherein R 15 is selected from the group consisting of optionally substituted C1-C6 alkyl, optionally substituted heterocyclyl, —C(O)R′, optionally substituted C3-C6 cycloalkyl, optionally substituted amino, optionally substituted aryl, and optionally substituted heteroaryl;
R′ is H or optionally substituted C1-C4 alkyl;
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5 , wherein X or Y, whichever is present, is O.
7. The compound of claim 1 , which is selected from the group consisting of
3-methoxy-5-(2-phenyl-5-(pyridin-4-yl)oxazol-4-yl)pyridin-2-amine;
(S)—N-(1-(4-(4-(6-amino-5-methoxypyridin-3-yl)-2-(4-fluorophenyl)oxazol-5-yl)pyrimidin-2-ylamino)propan-2-yl)-2-methoxyacetamide; and
(S)—N-(1-(4-(4-(5-amino-6-methoxypyrazin-2-yl)-2-(4-fluorophenyl)oxazol-5-yl)pyrimidin-2-ylamino)propan-2-yl)-2-methoxyacetamide.
8. A pharmaceutical composition comprising a compound of claim 1 , admixed with at least one pharmaceutically acceptable excipient.
9. The pharmaceutical composition of claim 8 , further comprising an additional therapeutic agent.
10. The compound of claim 1 , which is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.